



1645

PATENT APPLICATION
File No: 00-94

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Darrell C. Conklin, Zeren Gao, Catherine E. Lofton-Day, Theodore E. Whitmore
Serial No. : 10/038,241
Group Art Unit : 1645
Examiner :
Filed : October 19, 2001
For : SECRETED ALPHA-HELICAL PROTEIN ZLMDA24

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence, comprising:

1. Information Disclosure Statement
2. PTO-1449 Form
3. 24 References
4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 12, 2003.



Kim M. Goplen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Darrell C. Conklin, Zeren Gao, Catherine E. Lofton-Day, Theodore E. Whitmore
Serial No. : 10/038,241
Group Art Unit : 1645
Examiner :
Filed : October 19, 2001
For : SECRETED ALPHA-HELICAL PROTEIN ZLMDA24
Date Submitted : December 8, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Jennifer K. Johnson, J.D.
Registration No. 43,696

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			File No. 00-94		Serial No. 10/038,241
O 15 2003 DEC PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Applicant(s): Darrell C. Conklin, Zeren Gao, Catherine E. Lofton-Day, Theodore E. Whitmore		
		Filing Date: October 19, 2001		Group: 1645			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	1 033 401	09/06/00	EP			
	A2	99/27103	06/03/99	WO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)							
	A3		Jiang et al., "Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression," <i>Oncogene</i> (11):2477-2486, 1995.				
	A4		Su et al., "The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice," <i>Proc. Natl. Acad. Sci. USA</i> (95):14400-14405, 1998.				
	A5		Kallen et al., "Receptor Recognition Sites of Cytokines Are Organized as Exchangeable Modules," <i>J. Biol. Chem.</i> 274(17):11859-11867, 1999.				
	A6		Chaiken et al., "Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design," <i>TIBTECH</i> (14):369-375, 1996.				
	A7		Wamsley et al., 1997, (GenBank Acc. No. AC002127)				
	A8		National Cancer Institute, 1998, (GenBank Acc. No. AA922104)				
	A9		National Cancer Institute, 1997, (GenBank Acc. No. AA992398)				
	A10		National Cancer Institute, 1997, (GenBank Acc. No. AI239609)				
Examiner				Date considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			File No. 00-94	Serial No. 10/038,241	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Applicant(s): Darrell C. Conklin, Zeren Gao, Catherine E. Lofton-Day, Theodore E. Whitmore		
					Filing Date: October 19, 2001	Group: 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)							
		A11	National Cancer Institute, 1997, (GenBank Acc. No. AI203421)				
		A12	National Cancer Institute, 1997, (GenBank Acc. No. AI377781)				
		A13	National Cancer Institute, 1997, (GenBank Acc. No. AA905606)				
		A14	Hillier et al., 1997, (GenBank Acc. No. AA625640)				
		A15	Sequence from Incyte Pharmaceuticals, Inc., (No. INC2011166)				
		A16	Sequence from Incyte Pharmaceuticals, Inc., (No. INC2009226)				
		A17	National Cancer Institute, 1997, (GenBank Acc. No. AI239687)				
		A18	National Cancer Institute, 1997, (GenBank Acc. No. AA922104)				
Examiner				Date considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			File No. 00-94		Serial No. 10/038,241	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(Use several sheets if necessary)			Applicant(s): Darrell C. Conklin, Zeren Gao, Catherine E. Lofton-Day, Theodore E. Whitmore			
					Filing Date: October 19, 2001		Group: 1645	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)								
		A19	National Cancer Institute, 1997, (GenBank Acc. No. AW341494)					
		A20	National Cancer Institute, 1997, (GenBank Acc. No. AW631176)					
		A21	National Cancer Institute, 1997, (GenBank Acc. No. AI807251)					
		A22	National Cancer Institute, 1997, (GenBank Acc. No. AI674766)					
		A23	Hillier et al., 1997, (GenBank Acc. No. AA620653)					
		A24	National Cancer Institute, 1997, (GenBank Acc. No. AI242104)					
Examiner				Date considered				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								